The FDA has declined to approve MDMA therapy for treating PTSD, citing a need for further study. The decision comes after a phase III clinical trial showed promising results, but the agency wants more data before giving the green light. MDMA, also known as ecstasy, is a synthetic drug that has shown potential in reducing symptoms of post-traumatic stress disorder.

Source: https://www.nytimes.com/2024/08/09/health/fda-mdma-ptsd-delay.html